137 related articles for article (PubMed ID: 25745793)
1. New insights into the molecular profile of lung adenocarcinoma and implications for therapy.
Ganesh B; Devarakonda S; Govindan R
Expert Rev Anticancer Ther; 2015 Apr; 15(4):361-4. PubMed ID: 25745793
[TBL] [Abstract][Full Text] [Related]
2. Genomic alterations in lung adenocarcinoma.
Devarakonda S; Morgensztern D; Govindan R
Lancet Oncol; 2015 Jul; 16(7):e342-51. PubMed ID: 26149886
[TBL] [Abstract][Full Text] [Related]
3. A decade of advances in treatment for advanced non-small cell lung cancer.
Gettinger S; Lynch T
Clin Chest Med; 2011 Dec; 32(4):839-51. PubMed ID: 22054890
[TBL] [Abstract][Full Text] [Related]
4. Genomic profiling of lung adenocarcinoma patients reveals therapeutic targets and confers clinical benefit when standard molecular testing is negative.
Lim SM; Kim EY; Kim HR; Ali SM; Greenbowe JR; Shim HS; Chang H; Lim S; Paik S; Cho BC
Oncotarget; 2016 Apr; 7(17):24172-8. PubMed ID: 26992220
[TBL] [Abstract][Full Text] [Related]
5. Genomic landscape of squamous cell carcinoma of the lung.
Morgensztern D; Devarakonda S; Govindan R
Am Soc Clin Oncol Educ Book; 2013; ():348-53. PubMed ID: 23714544
[TBL] [Abstract][Full Text] [Related]
6. RET-rearranged lung adenocarcinomas with lymphangitic spread, psammoma bodies, and clinical responses to cabozantinib.
Mukhopadhyay S; Pennell NA; Ali SM; Ross JS; Ma PC; Velcheti V
J Thorac Oncol; 2014 Nov; 9(11):1714-9. PubMed ID: 25436805
[TBL] [Abstract][Full Text] [Related]
7. Cell death in cancer therapy of lung adenocarcinoma.
Zagryazhskaya A; Gyuraszova K; Zhivotovsky B
Int J Dev Biol; 2015; 59(1-3):119-29. PubMed ID: 26374533
[TBL] [Abstract][Full Text] [Related]
8. A never-smoker lung adenocarcinoma patient with a MET exon 14 mutation (D1028N) and a rapid partial response after crizotinib.
Mahjoubi L; Gazzah A; Besse B; Lacroix L; Soria JC
Invest New Drugs; 2016 Jun; 34(3):397-8. PubMed ID: 26892698
[TBL] [Abstract][Full Text] [Related]
9. Broad, Hybrid Capture-Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches.
Drilon A; Wang L; Arcila ME; Balasubramanian S; Greenbowe JR; Ross JS; Stephens P; Lipson D; Miller VA; Kris MG; Ladanyi M; Rizvi NA
Clin Cancer Res; 2015 Aug; 21(16):3631-9. PubMed ID: 25567908
[TBL] [Abstract][Full Text] [Related]
10. Increased S100A15 expression and decreased DNA methylation of its gene promoter are involved in high metastasis potential and poor outcome of lung adenocarcinoma.
Chen YC; Lin MC; Hsiao CC; Zheng YX; Chen KD; Sung MT; Chen CJ; Wang TY; Lin YY; Chang HC; Chen YM; Chang JC
Oncotarget; 2017 Jul; 8(28):45710-45724. PubMed ID: 28498804
[TBL] [Abstract][Full Text] [Related]
11. Personalized therapy on the horizon for squamous cell carcinoma of the lung.
Kim HS; Mitsudomi T; Soo RA; Cho BC
Lung Cancer; 2013 Jun; 80(3):249-55. PubMed ID: 23489560
[TBL] [Abstract][Full Text] [Related]
12. [Oncogenic drivers in daily practice improve overall survival in patients with lung adenocarcinoma].
Fournier C; Greillier L; Fina F; Secq V; Nanni-Metellus I; Loundou A; Garcia S; Ouafik L; Tomasini P; Barlesi F
Rev Mal Respir; 2016 Nov; 33(9):751-756. PubMed ID: 27017063
[TBL] [Abstract][Full Text] [Related]
13. Next-generation sequencing and clinical outcomes of patients with lung adenocarcinoma treated with stereotactic body radiotherapy.
Cassidy RJ; Zhang X; Patel PR; Shelton JW; Escott CE; Sica GL; Rossi MR; Hill CE; Steuer CE; Pillai RN; Ramalingam SS; Owonikoko TK; Behera M; Force SD; Fernandez FG; Curran WJ; Higgins KA
Cancer; 2017 Oct; 123(19):3681-3690. PubMed ID: 28608966
[TBL] [Abstract][Full Text] [Related]
14. Molecular targeted therapy in the treatment of advanced stage non-small cell lung cancer (NSCLC).
Kumarakulasinghe NB; van Zanwijk N; Soo RA
Respirology; 2015 Apr; 20(3):370-8. PubMed ID: 25689095
[TBL] [Abstract][Full Text] [Related]
15. Human lung adenocarcinoma cell cultures derived from malignant pleural effusions as model system to predict patients chemosensitivity.
Roscilli G; De Vitis C; Ferrara FF; Noto A; Cherubini E; Ricci A; Mariotta S; Giarnieri E; Giovagnoli MR; Torrisi MR; Bergantino F; Costantini S; Fenizia F; Lambiase M; Aurisicchio L; Normanno N; Ciliberto G; Mancini R
J Transl Med; 2016 Feb; 14():61. PubMed ID: 26928703
[TBL] [Abstract][Full Text] [Related]
16. Clinical Impact of Hybrid Capture-Based Next-Generation Sequencing on Changes in Treatment Decisions in Lung Cancer.
Rozenblum AB; Ilouze M; Dudnik E; Dvir A; Soussan-Gutman L; Geva S; Peled N
J Thorac Oncol; 2017 Feb; 12(2):258-268. PubMed ID: 27865871
[TBL] [Abstract][Full Text] [Related]
17. Genome-wide DNA Methylation Analysis Reveals
Niu X; Liu F; Zhou Y; Zhou Z; Zhou D; Wang T; Li Z; Ye X; Yu Y; Weng X; Zhang H; Ye J; Liao M; Liu Y; Chen Z; Lu S
Clin Cancer Res; 2017 Sep; 23(17):5003-5014. PubMed ID: 28490462
[No Abstract] [Full Text] [Related]
18. Fighting cancer drug resistance: Opportunities and challenges for mutation-specific EGFR inhibitors.
Juchum M; Günther M; Laufer SA
Drug Resist Updat; 2015 May; 20():12-28. PubMed ID: 26021435
[TBL] [Abstract][Full Text] [Related]
19. Emerging Biomarkers in Personalized Therapy of Lung Cancer.
Cagle PT; Raparia K; Portier BP
Adv Exp Med Biol; 2016; 890():25-36. PubMed ID: 26703797
[TBL] [Abstract][Full Text] [Related]
20. Retrospective Multicenter Study Investigating the Role of Targeted Next-Generation Sequencing of Selected Cancer Genes in Mucinous Adenocarcinoma of the Lung.
Righi L; Vatrano S; Di Nicolantonio F; Massa F; Rossi G; Cavazza A; Volante M; Votta A; Izzo S; Lo Iacono M; Ardissone F; Di Maio M; Novello S; Scagliotti GV; Papotti M
J Thorac Oncol; 2016 Apr; 11(4):504-15. PubMed ID: 26774193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
